News: Condor Software and Danforth Advisors Announce Strategic Biopharma Partnership.

Leader in clinical trial finance & accounting software.

Built by biopharma financial experts, Condor automates clinical accruals, forecasting, and scenario planning for FP&A and Accounting teams.

Trusted by Big 4 firms and 
publicly-traded biotech companies

The condor difference

A solution with proven results

Condor’s Automated Intelligence Platform gives Accounting & Finance teams an audit ready understanding of R&D expenses

$4B+

Study spend

100+

Clinical trials

>30%

Average Company Savings

Save money
Automate and Optimize Budget for Time, Cost, and Resources at Scale
Save time
Compatible with All Major Clinical Vendors and Accounting Software


Reduce risk
Trusted and Developed by Big 4 Audit and Pharma Experts
The condor difference

Condor’s automated
intelligence platform

Provides Accounting & FP&A teams with audit-ready accruals and precise forecasting.

Real-time intelligence for FP&A teams

Evaluate multiple study scenarios with the granularity of Excel, without the need for spreadsheets

Scale & streamline clinical accruals in your financial close

Unify and automate communication between accounting, finance and clinical teams as you reconcile clinical activity, budgets, and vendor reporting.

Reduce risk and mitigate critical audit matters

Designed to detect and prevent material misstatements with control mapping, compliance workflows, data validations, and comprehensive audit logs.

Integrations

Integrated and centralized financial management

Maximize Condor's potential by integrating with leading ERP, Procurement, FP&A, and Clinical Operations platforms. Ensure precision, efficiency, collaboration, and strategic oversight across your organization.

Testimonials

Trusted by the industry

Condor is refreshing!
It’s about time someone made clinical trial financial software that brings clarity and confidence to both us and our client.

Jen, Audit Partner
Big 4 Accounting Firm

Not only did Condor save us over $5M in one of our programs, but we’ve gone from 2 trials to 10 without adding more resources.”

JP, VP, Accounting
Public biotech company with several phase 2 and 3 trials targeting COVID-19 and rare disease

Before Condor, we struggled to close the books for one clinical program. After Condor, we’re not only closing the books faster, but also adding strategic value for our clinical partners and executive leadership team.”

Ellie, VP, Finance
Public biotech company expanding rapidly through M&A

See what we're up to

You'll find us at life science conferences throughout the year, eager to share our platform and thought leadership with you.

Get started today

Meet with our team to learn how Condor will accelerate your clinical trial finance process.